VR Adviser’s Gossamer Bio GOSS Stock Holding History

VR Adviser’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-21,838	Closed	-$20.9M	–	31
2022 Q3	$20.9M	Buy	+21,838	New	+$21.7M	3.23%	11

Other funds holding GOSS

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Weiss Asset Management Boston, Massachusetts $9.5B AUM 55.06% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

VR Adviser's GOSS Position: Q4 2022 in Review

VR Adviser sold out of Gossamer Bio (GOSS) in Q4 2022, closing a stake of 21,838 shares — an estimated $20.9M sold.

VR Adviser first reported a position in GOSS in Q3 2022 and held it in 1 quarter. The position peaked at $20.9M in Q3 2022. 118 funds tracked by Wall St. Rank hold GOSS as of Q4 2022.

VR Adviser reported no remaining Gossamer Bio position as of Q4 2022 after selling out during the quarter.
VR Adviser sold 21,838 Gossamer Bio shares in Q4 2022, an estimated $20.9M.
VR Adviser first reported a position in Gossamer Bio in Q3 2022 and held it in 1 quarter.
VR Adviser's Gossamer Bio position peaked at $20.9M in Q3 2022.
118 funds tracked by Wall St. Rank held Gossamer Bio as of Q4 2022.

Based on VR Adviser's 13F filing for Q4 2022, filed 14 Feb 2023.